Insiders lead, crossovers join in gene editing play Verve’s $63M round

GV leads A2 round, which came at a ‘very good step-up’ in valuation

When gene editing company Verve went out seeking new investors for its latest round of funding, existing shareholder GV decided it would rather lead the round itself.

GV and existing investors Arch Venture Partners, F-Prime Capital and Biomatics Capital joined new backers Wellington Capital and Casdin Capital in the $63 million series A2 round for Verve Therapeutics Inc., which is aiming to use gene

Read the full 632 word article

How to gain access

Continue reading with a
two-week free trial.